Clinical trial · Observational
A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)
A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy
NCT05903430CI-TRIAL-00094610MIDSECTIONrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine if the investigators are able to deliver highly focused, intense radiation to tumours in the abdominal region or chest cavity whilst limiting the dose to surrounding organs using a high field strength MR-Linac.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Abdominal Cancer | Malignant Abdominal Neoplasm | ALIAS | 0.90 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- > 85% success in delivery and completion of radiotherapy to patients recruited on protocol
- timeFrame
- 30 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: 1. Have no MRI contra-indications. 2. Eligible for abdominal SABR in accordance with the NHSE SABR Consortium Guidelines or eligible for central lung SABR in accordance with RTOG Guidelines. 3. Be able to give informed consent. 4. Anticipated life-expectancy \> 6 months. 5. Not more than 3 oligmetastatic sites treated in total per patients. 6. Performance status ≤ 2. 7. Willing to attend follow-up and have details collected on prospective basis for a minimum of 1 year. Exclusion criteria: 1. Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form. 2. Unable to tolerate MRI scans. 3. Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator make it undesirable for the patient to participate in the study. 4. Any evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator, make it undesirable for the patient to participate in the study. 5. Any patient known to have active hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
References
Publications (0)
Data not yet available
No reference posted for this study.